Navigation Links
Biovista Announces a Drug Repositioning Collaboration With Pfizer
Date:11/9/2010

h Biovista and their COSS technology to expand uses for our drugs and to help accelerate our clinical programs," said Don Frail, chief scientific officer of Pfizer's Indications Discovery Unit.

"Pfizer is an industry leader in terms of its drug repositioning efforts, supporting the vision that every drug may have potential beyond its initially developed uses," said Aris Persidis, President of Biovista. "Working with Pfizer on potential new indications may benefit expanded sets of patients with unmet medical needs, and is an opportunity to demonstrate the value of Biovista's COSS(TM) technology within the drug development workflow of bio-pharmaceutical companies," he added.

DISCLOSURE NOTICE: The information contained in this release is as of May 17, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about potential new uses for existing compounds that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications and supplemental drug applications for such new uses for existing compounds that may be filed for such compounds as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential of such new uses for existing compounds; and competitive developments. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

About Biovista:

Biovista is a privately held biotechnology company that finds novel uses for existing drugs, and pro
'/>"/>

SOURCE Biovista
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
2. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
3. Novus Biologicals Awards Contract to Biovista Inc. to Drive its Web-Based Novus Explorer Service
4. Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
5. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
6. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. Anesiva Announces Second Quarter 2008 Financial Results and Update
9. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
10. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Lexington,Kentucky and Queens, New York (PRWEB) October 02, ... is pleased to announce funding received to ... pathway in Alzheimer’s disease. A grant award from ... Institute on Aging (NIA), National Institutes of Health ... as Novel AD Therapeutics." The company also received ...
(Date:10/2/2014)... (PRWEB) October 02, 2014 Permian Plastics, ... in the St. Louis, Missouri, area on October 24th, ... become a leading plastic injection molder in the Midwest. ... and is a supplier to many Fortune 500 clients. ... support every step of the way, from concept to ...
(Date:10/2/2014)... 2014 At a time when many are ... has introduced a new kind of squeeze aimed at containing ... Scienceware® Squeeze Rite™ Wash Bottle , catalog no. F11717-0030. ... the bottle reduces the waste of reagents, solutions and other ... , “Easier to squeeze when compared to standard 500ml bottles, ...
(Date:10/2/2014)... 2014  NKT Therapeutics today announced that the ... Track designation to NKTT120, the company,s lead therapeutic ... disease.  NKTT120 is a humanized monoclonal antibody that ... that has been demonstrated to be a key ... sickle cell disease.  Fast Track designation is intended ...
Breaking Biology Technology:Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3Permian Plastics LLC Celebrates 20 Years As Leading Manufacturer of Plastic Molds 2New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2
... PARK, N.Y., Feb. 6 MINRAD International,Inc. (Amex: ... Company received a notice from,NYSE Alternext US LLC (the ... stock of the Company from the Exchange by filing ... to Section,1009(d) of the NYSE Alternext US Company Guide. ...
... Sky One Medical,Inc. ("China Sky One Medical" or ... leading,fully integrated pharmaceutical company producing over-the-counter drugs in,the ... the Company,s,Chief Financial Officer, Mr. Yu-bo (Stanley) Hao, ... Roth 21st Annual OC Growth Stock,Conference in Dana ...
... BIRMINGHAM, Ala., Feb. 6 BioCryst Pharmaceuticals, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2008. ... months ended December 31, 2008, the Company reported collaborative ... compared to $28.2 million for the three months ended ...
Cached Biology Technology:MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission 2MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission 3China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 2BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 3BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 4BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 5BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 6BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 7BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 8BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update 9
(Date:9/30/2014)... to using marijuana, new research, involving mice and published ... Journal of Leukocyte Biology , suggests that just ... should. That,s because a team of Italian scientists have ... long-term damage to the immune system. This damage may ... as multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra Automation, ... for the biotech and power generation industries, ... RECONN Bioprocess Manager, an easy-to-use and cost-effective ... towards bioprocess development laboratories. ... bioreactor and analyzer systems. Accessing and consolidating ...
(Date:9/29/2014)... study confirms that the exposure to tar tended to ... regular cigarettes. Similarly, exposure to nicotine tended to ... type of cigarette in several countries around the world. ... toxic chemicals in the smoke of these cigarettes are ... levels of chemicals in the smoke are not necessarily ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2Slim cigarette smokers not exposed to more harmful chemicals 2
... a group of human subjects to operate a robot-controlled joystick, ... "learns" to control certain muscle movements, the more likely it ... results, the investigators say, could alter rehabilitation approaches for people ... , In a report on the work in the ...
... and exercise performance measures of trained cyclists at high ... a lot -- up to 45% -- while others ... level. , Ten cyclists who took sildenafil at altitude ... kilometers by 15% compared to placebo trials at altitude. ...
... for breast cancer do not increase their life expectancy ... analysis by researchers from UC Davis, UCSF, the University ... addition, the researchers showed that tamoxifen is an extraordinarily ... per year of life saved. The study will be ...
Cached Biology News:New approach to vaccine development provides potent, long-lasting immunity 2New approach to vaccine development provides potent, long-lasting immunity 3Viagra improves high altitude exercise performance up to 45% for some 2Viagra improves high altitude exercise performance up to 45% for some 3Viagra improves high altitude exercise performance up to 45% for some 4Tamoxifen for breast cancer prevention does not benefit most women 2Tamoxifen for breast cancer prevention does not benefit most women 3
... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...
... Refrigerated Vapor Trap is specifically designed ... solvents such as DMSO and DMF ... constant temperature refrigeration system set at ... conditions for DMSO, while completely eliminating ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
Biology Products: